181 related articles for article (PubMed ID: 33634985)
21. Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol.
Oliver JM; Burg DL; Wilson BS; McLaughlin JL; Geahlen RL
J Biol Chem; 1994 Nov; 269(47):29697-703. PubMed ID: 7961959
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
Yang C; Merlin D
Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
[TBL] [Abstract][Full Text] [Related]
23. ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease.
Bao M; Wang K; Li J; Li Y; Zhu H; Lu M; Zhang Y; Fan Q; Han L; Wang K; Wang D; Gao Y; Peng B; Ming Z; Liu W
Acta Biomater; 2023 Apr; 161():250-264. PubMed ID: 36863680
[TBL] [Abstract][Full Text] [Related]
24. A Novel Nanomedicine Ameliorates Acute Inflammatory Bowel Disease by Regulating Macrophages and T-Cells.
Feng Z; Jiao L; Wu Z; Xu J; Gu P; Xu S; Liu Z; Hu Y; Liu J; Wu Y; Wang D
Mol Pharm; 2021 Sep; 18(9):3484-3495. PubMed ID: 34310145
[No Abstract] [Full Text] [Related]
25. Syk Inhibitor Attenuates Polymicrobial Sepsis in FcgRIIb-Deficient Lupus Mouse Model, the Impact of Lupus Characteristics in Sepsis.
Issara-Amphorn J; Chancharoenthana W; Visitchanakun P; Leelahavanichkul A
J Innate Immun; 2020; 12(6):461-479. PubMed ID: 32927460
[TBL] [Abstract][Full Text] [Related]
26. Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis.
Torres-Hernandez A; Wang W; Nikiforov Y; Tejada K; Torres L; Kalabin A; Wu Y; Haq MIU; Khan MY; Zhao Z; Su W; Camargo J; Hundeyin M; Diskin B; Adam S; Rossi JAK; Kurz E; Aykut B; Shadaloey SAA; Leinwand J; Miller G
Oncogene; 2019 Jun; 38(23):4512-4526. PubMed ID: 30742098
[TBL] [Abstract][Full Text] [Related]
27. Recent advance of spleen tyrosine kinase in diseases and drugs.
Shao Y; Zhang S; Zhang Y; Liu Z
Int Immunopharmacol; 2021 Jan; 90():107168. PubMed ID: 33264719
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
[TBL] [Abstract][Full Text] [Related]
29. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
30. SDH, a novel diarylheptane compound, is a potential treatment for inflammatory bowel disease by restoring epithelial barrier function.
Yang F; Zhu X; Li L; Wang Y; Xie Q; Cao Y; Yu Y; Zhang M; Li D; Li L; Liu Z; Zhang B; Chen Z; Deng S; Li Y
Biomed Pharmacother; 2022 Jul; 151():113080. PubMed ID: 35561427
[TBL] [Abstract][Full Text] [Related]
31. The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.
Can G; Ayvaz S; Can H; Demirtas S; Aksit H; Yilmaz B; Korkmaz U; Kurt M; Karaca T
J Crohns Colitis; 2015 Oct; 9(10):907-17. PubMed ID: 26116555
[TBL] [Abstract][Full Text] [Related]
32. Piceatannol is an effective inhibitor of IgE-mediated secretion from human basophils but is neither selective for this receptor nor acts on syk kinase at concentrations where mediator release inhibition occurs.
Miura K; Lavens-Phillips S; MacGlashan DW
Clin Exp Allergy; 2001 Nov; 31(11):1732-9. PubMed ID: 11696049
[TBL] [Abstract][Full Text] [Related]
33. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis.
Terc J; Hansen A; Alston L; Hirota SA
Eur J Pharm Sci; 2014 May; 55():12-9. PubMed ID: 24486481
[TBL] [Abstract][Full Text] [Related]
34. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
[TBL] [Abstract][Full Text] [Related]
35. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
36. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
Laroui H; Dalmasso G; Nguyen HT; Yan Y; Sitaraman SV; Merlin D
Gastroenterology; 2010 Mar; 138(3):843-53.e1-2. PubMed ID: 19909746
[TBL] [Abstract][Full Text] [Related]
37. Identification of Inhibitors of Integrin Cytoplasmic Domain Interactions With Syk.
Bakthavatsalam D; Craft JW; Kazansky A; Nguyen N; Bae G; Caivano AR; Gundlach CW; Aslam A; Ali S; Gupta S; Lin SY; Parthiban HD; Vanderslice P; Stephan CC; Woodside DG
Front Immunol; 2020; 11():575085. PubMed ID: 33488575
[TBL] [Abstract][Full Text] [Related]
38. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
[TBL] [Abstract][Full Text] [Related]
39. Suppression of Spleen Tyrosine Kinase (Syk) by Histone Deacetylation Promotes, Whereas BAY61-3606, a Synthetic Syk Inhibitor Abrogates Colonocyte Apoptosis by ERK Activation.
Dasgupta N; Thakur BK; Ta A; Dutta P; Das S
J Cell Biochem; 2017 Jan; 118(1):191-203. PubMed ID: 27293079
[TBL] [Abstract][Full Text] [Related]
40. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
